

recipients to provide a smoke-free workplace and to promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children.

#### *Executive Order 12372*

The Special Projects of National Significance Program has been determined to be a program subject to the provisions of Executive Order 12372, as implemented by 45 CFR part 100. Executive Order 12372 allows States the option of setting up a system for reviewing applications from within their States for assistance under certain Federal programs. The application packages to be made available under this notice will contain a listing of States which have chosen to set up a review system and will provide a State Single Point of Contact (SPOC) in the State for review. Applicants (other than Federally recognized Indian tribes) should contact their SPOCs as early as possible to alert them to the prospective applications and receive any necessary instructions on the State process. For proposed projects serving more than one State, the applicant is advised to contact the SPOC of each affected State. The due date for State process recommendations is 60 days after the appropriate deadline dates. The Health Resources and Services Administration does not guarantee that it will accommodate or explain its responses to State process recommendations received after the due date. (See "Intergovernmental Review of Federal Programs," Executive Order 12372, and 45 CFR part 100, for a description of the review process and requirements.)

#### OMB Catalog of Federal Domestic Assistance

The OMB Number for Special Projects of National Significance is 93.928.

Dated: November 5, 1996.

Ciro V. Sumaya,  
Administrator.

[FR Doc. 96-28933 Filed 11-8-96; 8:45 am]

BILLING CODE 4160-15-P

#### **Advisory Council; Notice of Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory body scheduled to meet during the month of December 1996:

*Name:* National Advisory Council on Nurse Education and Practice.

*Date and Time:* December 4-5, 1996, 8:30 a.m.

*Place:* Seneca Room, Silver Spring Holiday Inn, 8777 Georgia Avenue, Silver Spring, Maryland 20910.

The meeting is open to the public

*Agenda:* Updates on and discussion of Agency, Bureau and Division activities, and the legislation and budget status of programs; discussion of accreditation issues as they affect schools of nursing; review of nurse practitioner workforce trends, implications and options for the future.

Anyone wishing to obtain a roster of members, minutes of meeting or other relevant information should write or contact Ms. Melanie Timberlake, Executive Secretary, National Advisory Council on Nurse Education and Practice, Health Resources and Services Administration, Parklawn Building, Room 9-36, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-5786.

Agenda Items are subject to change as priorities dictate.

Dated: November 5, 1996.

Jackie E. Baum,

*Advisory Committee Management Officer,  
HRSA.*

[FR Doc. 96-28890 Filed 11-8-96; 8:45 am]

BILLING CODE 4160-15-P

#### **National Institutes of Health**

##### **Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development.

**ADDRESSES:** Licensing information and a copy of the U.S. patent applications referenced below may be obtained by contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 232; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

Cells Expressing Both Human CD4 and a Human Fusion Accessory Factor Associated With HIV Infection

EA Berger, Y Feng, CC Broder, PE Kennedy (NIAID)

Serial No. 60/010,854 filed 30 Jan 96

HIV-1 infects target cells by first binding to CD4, a receptor on the target cell membrane. The virus and target cell membranes then fuse, allowing the virus to enter the target cell. It has previously been determined that CD4 alone is not sufficient to allow entry, but that another factor specific to human cells is also required. The current invention embodies the identification of a cDNA encoding a protein, designated "fusin," which demonstrates properties expected of a fusion co-factor for T-cell line tropic HIC-1 isolates. Fusin is a member of the 7-transmembrane segment (7-TMS) superfamily of G-protein-coupled receptors. While this cDNA has previously been cloned, its potential role as an accessory protein necessary for HIV infection is novel to the current invention. The invention, therefore, should represent a valuable tool to be used in the production of transgenic mice and of cell lines for the study of HIV infection. In addition, the invention may itself represent a potential therapeutic agent against HIV or target for agents acting to block entry of HIV into target cells. This technology was reported in *Science* 272:809-810 (1996); *Chemical and Engineering News*, p. 7 (May 13, 1996); *BioWorld Today*, pp. 1-2 (May 13, 1996); *Biotechnology News*, 16(13): 1-2 (1996); and *BioWorld Today*, pp. 1, 3 (June 21, 1996). (portfolios: Infectious Diseases—Research Materials; Infectious Diseases—Miscellaneous; Infectious Diseases—Therapeutics, anti-virals, AIDS)

CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection

C Combadiere, Y Feng, EA Berger, G Alkhatib, PM Murphy, CC Broder (NIAID)

Serial No. 60/018,508 filed 28 May 1996

This invention concerns a novel macrophage-selective CC chemokine receptor, designated "CC CKR5," which is a necessary cofactor for the infection of target cells by macrophage-tropic HIV isolates. Macrophage-tropic HIV isolates represent the predominant type of isolates from infected persons and appear to be preferentially transmitted between individuals. The invention embodies the CC CKR5 genetic sequence, cell lines and transgenic mice, the cells of which coexpress human CD4 and CC CKR5, and which may represent valuable tools for the study of HIV infection and for screening anti-HIV agents. The invention also embodies anti-CC CKR5 agents that block HIV env-mediated membrane fusion associated with HIV entry into human CD4-positive target cells or